Scientists at the FDA are concerned about Eli Lilly’s Alzheimer’s drug donanemab, questioning the use of PET scans to limit patient eligibility and weighing the risks against benefits. An analysis suggests a higher risk of death for patients taking the drug. The FDA is convening experts to address these issues.
Source link
FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted
